★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Stock Profile
Novo Nordisk A/S (NOVOB) Moat Analysis
Novo Nordisk A/S
NOVOB · Nasdaq Copenhagen
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Novo Nordisk A/S is a Danish healthcare company focused on diabetes, obesity and rare disease. H1 2026 reported sales were 67.6% Diabetes care, 26.5% Obesity care and 5.9% Rare disease, although a DKK 26.8 billion US 340B rebate-provision reversal inflated the reported diabetes mix; the adjusted mix was approximately 64.2%, 29.7% and 6.1%. The defensible company-specific moats are concentrated in diabetes and obesity: still-valuable but finite semaglutide IP, technically demanding manufacturing scale and know-how, and contested obesity-franchise trust. Canada semaglutide loss of exclusivity is already lowering realised prices, while roughly DKK 3 billion of Q2 manufacturing right-sizing costs argues against treating installed capacity as a scarce choke point. Novo retained 30.1% diabetes value share and 59.6% branded GLP-1 obesity volume share in MAT November 2025, and Wegovy pill exceeded five million US prescriptions by H1 reporting. The rare-disease portfolio has specialty economics but no evidenced company-specific durable moat. Key pressures are Lilly competition, patent expiry, payer pricing, capacity execution and next-generation therapies.
Primary segment
Diabetes care
Market structure
Oligopoly
Market share
30.1% (reported)
HHI: —
Coverage
3 segments · 8 tags
Updated 2026-08-08
Segments
Diabetes care
Diabetes pharmaceuticals (GLP-1 for type 2 diabetes, insulin, and related therapies)
Revenue
67.6%
Structure
Oligopoly
Pricing
moderate
Share
30.1% (reported)
Peers
Obesity care
Branded obesity pharmacotherapy (chronic weight management; GLP-1-based anti-obesity medicines)
Revenue
26.5%
Structure
Duopoly
Pricing
moderate
Share
59.6% (reported)
Peers
Rare disease
Rare disease therapeutics (haemophilia, growth hormone, and other rare endocrine/blood disorder treatments)
Revenue
5.9%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Moat Claims
Diabetes care
Diabetes pharmaceuticals (GLP-1 for type 2 diabetes, insulin, and related therapies)
Revenue share uses H1 2026 reported Diabetes care sales of DKK 118,448 million over reported group sales of DKK 175,311 million. Reported diabetes sales include the DKK 26.8 billion US 340B rebate-provision reversal; adjusted Diabetes care sales were DKK 95,365 million and declined 5% at CER.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Key GLP-1 franchise remains protected by patents and active defense against generics, but international patent expiries and share losses make the moat less durable than pure patent duration suggests.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Patent challenges and settlements accelerating generic/biosimilar entry
- Product-specific patent cliffs (finite duration)
- Adverse litigation outcomes narrowing claims
Leading indicators
- Key patent litigation decisions and settlement terms (timing of generic entry)
- Biosimilar/ANDA pipeline filings and approvals
- Patent expiry timeline changes by jurisdiction
Counterarguments
- Strong IP does not prevent share loss to differentiated competitors (e.g., new GLP-1/GIP classes)
- Payer formularies can shift share even before patent expiry via rebates and preferred placement
Capex Knowhow Scale
Supply
Capex Knowhow Scale
Strength
Durability
Confidence
Evidence
Novo has a large, technically demanding API and fill-finish footprint, but capacity can be built by rivals and Q2 right-sizing charges show that scarcity is no longer uniformly constraining output.
Capex Knowhow Scale moat: definition, examples, and stocks
Erosion risks
- Competitors add large-scale capacity (internal or via CMOs)
- Manufacturing quality issues or regulatory shutdowns
- Technology shifts (new modalities) reducing relevance of existing capacity
Leading indicators
- Drug shortage notifications and backorder duration
- Capex announcements and commissioning milestones
- Fill-finish throughput and product allocation updates
Counterarguments
- Capacity advantages can be competed away with time and capital
- Supply constraints can also cap growth and reduce near-term revenue realization
Obesity care
Branded obesity pharmacotherapy (chronic weight management; GLP-1-based anti-obesity medicines)
Revenue share uses H1 2026 reported Obesity care sales of DKK 46,495 million over reported group sales of DKK 175,311 million. Adjusted Obesity care sales were DKK 44,064 million and increased 19% at CER, led by Wegovy volume but partly offset by lower realised prices.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Wegovy injection and pill benefit from patent protection cited by the company, but the key semaglutide molecule expires earlier in some non-US markets and competition has intensified.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Patent challenges and negotiated early-entry settlements
- Emergence of new drug classes with superior efficacy/safety
- Regulatory reforms weakening exclusivity
Leading indicators
- Semaglutide-related IP litigation updates
- Competing oral or next-gen obesity drug approvals
- Formulary positioning changes vs competitors
Counterarguments
- Even with IP, share can shift to better clinical profiles (efficacy/tolerability) from rivals
- Government/payer pressure can reduce net price independent of exclusivity
Capex Knowhow Scale
Supply
Capex Knowhow Scale
Strength
Durability
Confidence
Evidence
API and fill-finish scale remain technically demanding and capital intensive, but competitors are adding capacity and Novo is now absorbing costs to right-size parts of its own manufacturing footprint.
Capex Knowhow Scale moat: definition, examples, and stocks
Erosion risks
- Competitor capacity catch-up (internal/CMO)
- Manufacturing reliability and quality risks
- Shift to modalities with different manufacturing constraints
Leading indicators
- Supply constraint disclosures and shipment allocation changes
- Capex pace and new site ramp milestones
- Competitor supply expansion announcements
Counterarguments
- Capacity is not a permanent moat; scale can be purchased over time
- Supply shortages can create customer dissatisfaction and reputational risk
Brand Trust
Demand
Brand Trust
Strength
Durability
Confidence
Evidence
Novo remains a leading branded obesity franchise and the oral launch broadened adoption, but share declined in 2025 and the demand-side advantage is contested by Lilly and newer mechanisms.
Brand Trust moat: definition, examples, and stocks
Erosion risks
- Rapid innovation cycles (new oral entrants, new mechanisms)
- Safety/tolerability events impacting perception
- Aggressive competitor contracting and access wins
Leading indicators
- Global branded obesity market share trend vs Lilly
- Persistence/adherence and discontinuation rates
- Net price evolution (rebates, negotiated prices)
Counterarguments
- Share leadership can be driven by supply/availability, not necessarily brand trust
- Competitors with better outcomes or easier administration can flip prescriber preference quickly
Rare disease
Rare disease therapeutics (haemophilia, growth hormone, and other rare endocrine/blood disorder treatments)
Revenue share uses H1 2026 reported Rare disease sales of DKK 10,368 million over reported group sales of DKK 175,311 million. Adjusted Rare disease sales were DKK 9,122 million and increased 2% at CER; no company-specific durable moat is evidenced for this mixed portfolio.
Insufficient segment-specific evidence to assign a moat claim.
Evidence
Patent status for products with marketing authorisation
Annual report patent table shows Ozempic US/China/Japan/Europe active-ingredient patent expiries.
Novo Nordisk has lost volume market share in the GLP-1 market places
Confirms that patent protection has not prevented competitive share losses.
loss of exclusivity for semaglutide has led to lower realised prices
Current evidence that molecule-level IP erosion is already affecting economics in Canada despite broadly stable Novo volumes.
Novo Nordisk acquired three fill-finish sites
Direct evidence of strategic control over a key injectable-drug bottleneck.
investments in additional capacity for active pharmaceutical ingredient (API) production and fill-finish capacity
Shows ongoing capacity build beyond the 2024 Catalent-site transaction.
Showing 5 of 12 sources.
Risks & Indicators
Erosion risks
- Patent challenges and settlements accelerating generic/biosimilar entry
- Product-specific patent cliffs (finite duration)
- Adverse litigation outcomes narrowing claims
- Competitors add large-scale capacity (internal or via CMOs)
- Manufacturing quality issues or regulatory shutdowns
- Technology shifts (new modalities) reducing relevance of existing capacity
Leading indicators
- Key patent litigation decisions and settlement terms (timing of generic entry)
- Biosimilar/ANDA pipeline filings and approvals
- Patent expiry timeline changes by jurisdiction
- Drug shortage notifications and backorder duration
- Capex announcements and commissioning milestones
- Fill-finish throughput and product allocation updates
Research NOVOB elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.